Shared on 05 Nov 25
FPH: Fair Value Assessment Will Remain Steady With Minor Discount Rate Adjustment
Analysts have marginally increased their price target for Fisher & Paykel Healthcare to $36.61. This reflects minor adjustments in company fundamentals and updated discount rate assumptions.
Shared on 22 Oct 25
Analysts have maintained their price target for Fisher & Paykel Healthcare at $36.61 per share, citing stable forecasts for discount rate, revenue growth, profit margin, and forward price-to-earnings ratios. Minimal changes were observed in the underlying model inputs.
Shared on 08 Oct 25
Fair value Increased 1.50%Analysts have modestly increased their price target for Fisher & Paykel Healthcare from $36.06 to $36.61 NZD, reflecting updated forecasts for slightly higher revenue growth and improved profitability expectations. Valuation Changes Fair Value Estimate has risen slightly from NZ$36.06 to NZ$36.61 per share.
Shared on 19 Sep 25
Fair value Increased 1.07%Fisher & Paykel Healthcare's consensus revenue growth and future P/E forecasts both saw only marginal improvements, underpinning the slight increase in the analyst price target from NZ$35.68 to NZ$36.06. What's in the News Fisher & Paykel Healthcare announced an ordinary unfranked dividend of NZD 0.28235294 per share for the six months ended March 31, 2025, payable on July 4, 2025.